Search

Patient response to antipsychotic drugs varies and may be related to clinical and genetic heterogeneity. This study aimed to determine the performance of clinical, genetic, and hybrid models to predict the response of first episode of psychosis (FEP). patients to the antipsychotic risperidone. We evaluated 141 antipsychotic-naïve FEP patients before and after 10 weeks of risperidone treatment. Patients who had a response rate equal to or higher than 50% on the Positive and Negative Syndrome Scale were considered responders (n = 72; 51%). Analyses were performed using a support vector machine (SVM), k-nearest neighbors (kNN), and random forests (RF). Clinical and genetic (with single-nucleotide variants [SNVs]) models were created separately. Hybrid models (clinical+genetic factors) with and without feature selection were created. Clinical models presented greater balanced accuracy 63.3% (confidence interval [CI] 0.46-0.69) with the SVM algorithm than the genetic models (balanced accuracy: 58.5% [CI 0.41-0.76] - kNN algorithm). The hybrid model, which included duration of untreated psychosis, Clinical Global Impression-Severity scale scores, age, cannabis use, and 406 SNVs, showed the best performance (balanced accuracy: 72.9% [CI 0.62-0.84] - RF algorithm). A hybrid model, including clinical and genetic predictors, can provide enhanced predictions of response to antipsychotic treatment., Competing Interests: RAB declares personal fees and non-financial support from Janssen and Ache Laboratórios Farmacêuticos, grants, and personal fees from Roche, outside the submitted work. AG declares personal fees and non-financial support from Janssen, Daiichi Sankyo, Lundbeck, Teva, Cristalia, and Ache Laboratórios Farmacêuticos outside the submitted work. CN declares personal fees and non-financial support from Janssen, Daiichi Sankyo, Lundbeck, Teva, and Ache Laboratórios Farmacêuticos outside the submitted work. No other conflicts of interest declared concerning the publication of this article.